Analyses of the first three patients at 6 months post-treatment showed increases in white matter and myelin and improvements on validated functional scales To date, 5 patients have been treated in the ongoing Phase 1/2 First-in-Human clinical trial with favorable safety and tolerability Encouraging early data support further development of rAAV-Olig001-ASPA as a potential therapeutic…
Read more